Adial Pharmaceuticals (ADIL) Price & Analysis

Compare

573 Followers

ADIL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.22 - $1.30

Previous CloseN/A

Volume36.45K

Average Volume (3M)3.37M

Market Cap

$8.60M

Enterprise Value-$2.70M

Total Cash (Recent Filing)$5.91M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Nov 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding21,828,215

10 Day Avg. Volume976,374

30 Day Avg. Volume3,365,606

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.31

Enterprise Value/Revenue-4.80K

Enterprise Value/Gross Profit6.38K

Enterprise Value/Ebitda0.33

Forecast

1Y Price Target

$2.00

Price Target Upside440.54% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

LeadershipNew leadership appointment with Vinay Shah as the company's CFO brings over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy.

Regulatory ApprovalAdial announced positive top-line results from its pharmacokinetics (PK) study of AD04, which confirmed the relative bioavailability to marketed ondansetron and no food effects.

Regulatory FeedbackAdial announced the positive feedback it received from US and EU regulators around its AD04 program, following regulatory meetings.

Bears Say

Financial OverhangAdditional capital is required to advance this program and as such, a Hold rating is maintained as the company works to resolve its financial overhang.

Financial PerformanceAdial filed its 10-Q, reporting 3Q24 results with a net loss of ($2.2M) and ended the period with $5.2M in cash on the balance sheet.

Adial Pharmaceuticals News

Adial encouraged by U.S. Senate support for extended AUD trial endpoints

Adial Pharmaceuticals (ADIL) “applauded” recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance...

4h ago

ADIL

Adial Pharmaceuticals expects cash to fund operations into Q2 of 2026

The company reported Q2 results. Cash and cash equivalents were $5.9 million as of June 30, 2025, compared...

6d ago

ADIL

Adial Pharmaceuticals completes EOP2 FDA meeting

Adial Pharmaceuticals (ADIL) announced the completion of a successful End of Phase 2 meeting, EOP2M, with the Food...

14d ago

ADIL

ADIL Upcoming Earnings Report: What to Expect?

Adial Pharma (ADIL) is scheduled to report 2nd quarter earnings on 08/13/2025. Regarding Q2 estimates, Wall Street analysts...

9d ago

ADIL

Adial Pharmaceuticals Enters New Sales Agreement

An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. On August 1, 2025, Adial Pharmaceuticals entered...

19d ago

ADIL

Adial Pharmaceuticals Approves Share Increase at Annual Meeting

Adial Pharmaceuticals ( ($ADIL) ) has provided an announcement. On August 1, 2025, Adial Pharmaceuticals held its Annual...

19d ago

ADIL

Adial Pharmaceuticals Regains Nasdaq Compliance After Offering

Adial Pharmaceuticals ( ($ADIL) ) just unveiled an update. On May 23, 2025, Adial Pharmaceuticals received a letter...

1M ago

ADIL

Adial regains compliance with Nasdaq’s Equity Listing requirement

Adial Pharmaceuticals (ADIL) announced that it received notice from Nasdaq on July 14, 2025 that the Company has...

1M ago

ADIL

Adial Pharmaceuticals Raises $3.6 Million to Meet Nasdaq Rules

Adial Pharmaceuticals ( ($ADIL) ) has shared an update. On May 23, 2025, Adial Pharmaceuticals received a notice...

1M ago

ADIL

Adial Pharmaceuticals files PCT patent application for core assets

Adial Pharmaceuticals (ADIL) announced the filing of an update to the provisional patent application for AD04 which was...

1M ago

ADIL

Adial Pharmaceuticals secures U.S.-based manufacturing through agreements

Adial Pharmaceutical (ADIL) announced the recent execution of agreements for the production of AD04, supporting both the completion...

2M ago

TMO

ADIL

Adial Pharmaceuticals Completes $3.6M Public Offering

The latest announcement is out from Adial Pharmaceuticals ( ($ADIL) ). On June 18, 2025, Adial Pharmaceuticals completed...

2M ago

ADIL

Adial Pharmaceuticals prices 11.1M shares at 32.51c in public offering

Adial Pharmaceuticals (ADIL) announced the pricing of its “reasonable best efforts” public offering for the purchase and sale...

2M ago

ADIL

Adial Pharmaceuticals Reschedules 2025 Annual Meeting Date

An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. Adial Pharmaceuticals, Inc. has announced a change...

2M ago

ADIL

ADIL FAQ

What was Adial Pharmaceuticals Inc’s price range in the past 12 months?

Adial Pharmaceuticals Inc lowest stock price was $0.22 and its highest was $1.30 in the past 12 months.

What is Adial Pharmaceuticals Inc’s market cap?

Adial Pharmaceuticals Inc’s market cap is $8.60M.

When is Adial Pharmaceuticals Inc’s upcoming earnings report date?

Adial Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2025 which is in 90 days.

How were Adial Pharmaceuticals Inc’s earnings last quarter?

Adial Pharmaceuticals Inc released its earnings results on Aug 14, 2025. The company reported -$0.184 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.004.

Is Adial Pharmaceuticals Inc overvalued?

According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adial Pharmaceuticals Inc pay dividends?

Adial Pharmaceuticals Inc does not currently pay dividends.

What is Adial Pharmaceuticals Inc’s EPS estimate?

Adial Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Adial Pharmaceuticals Inc have?

Adial Pharmaceuticals Inc has 21,828,215 shares outstanding.

What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?

Adial Pharmaceuticals Inc reported an EPS of -$0.184 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -2.5%.

Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ADIL

Company Description

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals (ADIL) Earnings & Revenues

Historic Earnings Reports

ADIL Stock 12 Month Forecast

Average Price Target

$2.00

▲(440.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.5784615384615385,0.696923076923077,0.8153846153846154,0.9338461538461539,1.0523076923076924,1.1707692307692308,1.2892307692307692,1.4076923076923078,1.5261538461538462,1.6446153846153846,1.763076923076923,1.8815384615384616,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.5784615384615385,0.696923076923077,0.8153846153846154,0.9338461538461539,1.0523076923076924,1.1707692307692308,1.2892307692307692,1.4076923076923078,1.5261538461538462,1.6446153846153846,1.763076923076923,1.8815384615384616,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.5784615384615385,0.696923076923077,0.8153846153846154,0.9338461538461539,1.0523076923076924,1.1707692307692308,1.2892307692307692,1.4076923076923078,1.5261538461538462,1.6446153846153846,1.763076923076923,1.8815384615384616,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.15,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >